Clinical efficacy of methyl aminolevulinate (Metvix®) photodynamic therapy

Journal of Dermatological Treatment

Volumn 14, Issue SUPPL. 3, 2003, Pages 15-22

  Foley, P ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

5 aminolevulinic acid; Actinic keratosis; Basal cell carcinoma; Photodynamic therapy (PDT); Squamous cell carcinoma

Indexed keywords

AMINOLEVULINIC ACID METHYL ESTER; FLUOROURACIL; PHOTOSENSITIZING AGENT; UNCLASSIFIED DRUG;

ACTINIC KERATOSIS; ARTICLE; BASAL CELL CARCINOMA; BLISTER; BURNING SENSATION; CANCER SURGERY; CLINICAL TRIAL; CREAM; CRYOTHERAPY; DRUG EFFICACY; DRUG SAFETY; EROSION; ERYTHEMA; HUMAN; HYPOPIGMENTATION; NON MELANOMA SKIN CANCER; PAIN; PHOTODYNAMIC THERAPY; PHOTOTOXICITY; PRIORITY JOURNAL; RECURRENT DISEASE; SIDE EFFECT; SKIN CANCER; SKIN TINGLING; TREATMENT OUTCOME;

EID: 0344010480     PISSN: 09546634     EISSN: None     Source Type: Journal    
DOI: 10.1080/753267206     Document Type: Article

References (12)

1. Peng Q, Soler AM, Warloe T et al, Selective distribution of porphyrins in skin thick basal cell carcinoma after topical application of methyl 5-aminolevulinate. J Photochem Photobiol B (2001) 62: 140-145.
2. Braathen L, Paredes B, Saksela et al, An open exploratory (phase I/II) study of Metvix®) cream 80 mg/g and 160 mg/g in patients with primary actinic keratosis. J Eur Acad Dermatol Venereol (2000) 14(S1): 38.
3. Szeimies RM, Karrer S, Radakovic-Fijan S et al, Photodynamic therapy using topical methyl 5-aminolevulinate compared with cryotherapy for actinic keratosis: A prospective, randomized study. J Am Acad Dermatol (2002) 47: 258-62.
4. Freeman M, Vinciullo C, Francis D et al, A comparison of photodynamic therapy using topical methyl aminolevulinate (Metvix®) with single cycle cryotherapy in patients with actinic keratosis: a prospective, randomized study. J Dermatol Treat (2003) 14: 99-106.
5. Pariser DM, Lowe NJ, Stewart DM et al, Photodynamic therapy with topical methyl aminolevulinate for actinic keratosis: results of a prospective randomized multicenter trial. J Am Acad Dermatol (2003) 48: 227-32.
6. Basset-Seguin N, Bachmann I, Pavel S et al, A dose finding study of photodynamic therapy with Metvix® in patients with basal cell carcinoma. J Eur Acad Dermatol Venereol (2000) 14(S1):39 (abstr).
7. Basset-Seguin N, Ibbotson S, Emtestam L, Photodynamic therapy using Metvix® is as efficacious as cryotherapy in BCC, with better cosmetic results. J Eur Acad Dermatol Venereol (2001) 15(S2): 226.
8. Rhodes L, de Rie M, Engtrom Y et al, Photodynamic therapy using topical methyl aminolevulinate versus surgery for nodular basal cell carcinoma: results of a multicentre randomised prospective trial. Arch Dermatol (In press).
9. Vinciullo C, Elliott T et al, Photodynamic therapy with methyl aminolevulinate 160mg/g cream in patients with basal cell carcinoma with a risk of complications and poor cosmetic outcome using conventional therapy. Poster presentation at 9th World Congress of Cancers of the Skin, Seville 7-10 May 2003.
10. Horn M, Wolf P, Wulf HC, Topical methyl aminolevulinate photodynamic therapy in patients with basal cell carcinoma prone to complications and poor cosmetic outcome with conventional treatment. Br I Dermatol (in press).
11. Foley et al, A phase III randomized study comparing photodynamic therapy (PDT) using Metvix® or placebo cream in nodular basal cell carcinoma (BCC). Australas J Dermatol (2003) 44: A5.
12. Tope WD, Menter A, El-Azhary RA et al, Randomized prospective comparison of topical methylaminolevulinate photodynamic therapy versus placebo photodynamic therapy in nodular basal cell carcinoma. Poster presentation at 9th World Congress of Cancers of the Skin, Seville 7-10 May 2003.